RA Capital Healthcare Fund LP 3
3 · SpyGlass Pharma, Inc. · Filed Feb 5, 2026
Insider Transaction Report
Form 3
RA CAPITAL MANAGEMENT, L.P.
Director10% Owner
Holdings
- (indirect: See footnotes)
Series C-1 Preferred Stock
[F1][F2][F3]→ Common Stock (1,150,941 underlying) - (indirect: See footnotes)
Series C-1 Preferred Stock
[F1][F2][F4]→ Common Stock (767,294 underlying) - (indirect: See footnotes)
Series C-2 Preferred Stock
[F1][F2][F3]→ Common Stock (1,150,941 underlying) - (indirect: See footnotes)
Series C-2 Preferred Stock
[F1][F2][F4]→ Common Stock (767,294 underlying) - (indirect: See footnotes)
Series D Preferred Stock
[F1][F2][F3]→ Common Stock (222,591 underlying) - (indirect: See footnotes)
Series D Preferred Stock
[F1][F2][F4]→ Common Stock (272,056 underlying)
Footnotes (4)
- [F1]All shares of the preferred stock, par value $0.00001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
- [F2]RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- [F3]Held directly by the Fund.
- [F4]Held directly by the Nexus Fund III.